Abstract:Yudisia Ausi, 1, 2 Melisa Intan Barliana, 2, 3 Maarten J Postma, 3, 4 Auliya A Suwantika 3, 5 1 Doctor Program in Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia; 2 Department of Biological Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia; 3 Center of Excellence for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia; 4 Department of Health Sciences, University Medical Center Groningen, University of Groningen, Groningen, Netherlands; 5 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jatinangor, Indonesia Correspondence: Auliya A Suwantika, Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jalan Raya Bandung Sumedang KM 21 Jatinangor, Sumedang, 45363, Indonesia, Tel +62 22 84288828, Email Pharmacogenetics is a promising approach in future personalized medicine. This field holds excellent prospects for healthcare quality acceleration. It promotes the transition to the precision medicine era, whereby a health treatment is driven by a deeper understanding of individual characteristics by interpreting the underlying genomic variation. Pharmacogenetics has been developing rapidly since the human genome project. Many pharmacogenetics studies have shown the association between genetic variants and therapy outcomes. Several pharmacogenetics working groups have recommended guidelines for the clinical application of pharmacogenetics. However, the development of pharmacogenetics in low- and middle-income countries (LMICs) is still retarded behind. The problems mainly include clinical evidence, technology, policy and regulation, and human resources. Currently, available genome and drug effect data in LMICs are scarce. Pharmacogenetics development should be escalated with evidence proof through research collaboration across countries. The challenges of pharmacogenetics implementation are discussed comprehensively in this article, along with the prospect of pharmacogenetics-guided personalized medicine in developed countries. Stepwise is expected to help the researchers and stakeholders define the problem that hindered the pharmacogenetics application. Keywords: pharmacogenetics, implementation, LMICs, personalized medicine Every organism has hereditary material called genes. Nearly every human cell has Deoxyribonucleic acid (DNA), which carries genetic information. DNA contains code for development and functioning. As the genetic material, DNA codes for amino acids, the building blocks of protein. 1 Each protein has its function in creating particular anatomical features or physiological processes. Genetic variation may alter the protein function or expression levels. 2 Several studies have discovered the relevance of inter-individual genetic variation with individual drug responses that support therapy decisions, called pharmacogenetics. 3 Even though genetic variations (genotype) influence drug response and the incidence of adverse drug reaction (ADR) phenotypes in an individual is considered the focus of pharmacogenetics study, translations of the available genomic information into actionable clinical recommendations still lagged behind. 4 The term "pharmacogenetics" was first created by Friedrich Vogel in 1959. 5 In the last decade, the human genome project has accelerated pharmacogenetics discoveries. 6,7 Pharmacogenetics is rapidly evolving in developed countries like the United States of America (USA). Private sectors, educational institutions, and the government significantly increase research and create an adequate bioinformatics environment. Cutting-edge technology has rapidly evolved, including the high throughput sequencing platform. 8 Genetic information in the form of DNA sequences from individual laboratories and large-scale projects worldwide is documented in a database to provide access to the scientific community. 9,10 The USA Food and Drugs Administration (FDA) has also offered expanded information related to drug-gene interaction on its website ( www.fda.gov ) and drug labels. 9,11 To apply pharmacogenetics knowledge in routine clinical practice, several initiatives of pharmacogenetics implementation in clinical practice have started to emerge. Evidence-based guidelines for specific drug combinations and genotypes or predicted phenotypes are crucial to improve drug safety and enhance clinical effectiveness. 12,13 Globally, evidence-based guidelines have been developed for pharmacogenetics by various committees, such as the Clinical Pharmacogenetics Implementation Consortium (CPIC), the F -Abstract Truncated-

The 1200 Patients Project: Creating a New Medical Model System for Clinical Implementation of Pharmacogenomics

The Pharmacogenomics Global Research Network Implementation Working Group: global collaboration to advance pharmacogenetic implementation

Pharmacogenomics Clinical Decision Support System:A Review

CLINICAL IMPLEMENTATION OF PREEMPTIVE PHARMACOGENOMICS TESTING FOR PERSONALIZED MEDICINE AT AN ACADEMIC MEDICAL CENTER

Implementation of a pharmacist-guided pharmacogenomics dosing service at a rural NCI-designated comprehensive cancer center

Pharmacogenetics Clinical Decision Support Systems for Primary Care in England: Co-Design Study

Barriers and Solutions in Clinical Implementation of Pharmacogenomics for Personalized Medicine

Implementing a Pharmacist-Led Primary Care Pharmacogenomics Medication Management Service

One Step Ahead in Realizing Pharmacogenetics in Low- and Middle-Income Countries: What Should We Do?

Implementation of preemptive DNA sequence–based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study

Challenges of development and implementation of point of care pharmacogenetic testing

Implementing pharmacogenomic testing in Australian general practice: an exploratory qualitative study

Building an Information System to Facilitate Pharmacogenomics Clinical Translation with Clinical Decision Support

PillHarmonicsTM: An Orchestrated Pharmacogenetics Medication Clinical Decision Support Service

The implementation of pharmacogenomics into UK general practice: a qualitative study exploring barriers, challenges and opportunities

PHARMACOGENOMICS: Driving Personalized Medicine

Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing

Clinical Utility and Implementation of Pharmacogenomics for the Personalisation of Antipsychotic Treatments

Pharmacogenomics: current status and future perspectives

Progress and problem in the clinical application of pharmacogenomics

Ensuring equity: Pharmacogenetic implementation in rural and tribal communities